-
What are the most authoritative children's hospitals in the UK, what cutting-edge therapies for the treatment of pediatric neuroblastoma?
Time of Update: 2022-11-04
1In 2020, a phase I clinical trial conducted by Great Ormond Street Hospital for Children (GOSH) and the Great Ormond Street Institute for Child Health (UCL GOS ICH) at University College London showed that CAR-T cell therapy showed good early results in childhood neuroblastoma, opening the door to further clinical trials of this approach.
-
The Magic Bullet to Cancer in the New Century takes stock of 14 ADCs available worldwide
Time of Update: 2022-11-04
Its constituent structure is conjugated by the chimeric antibody IgG1 targeting CD30 and the tubulin inhibitor MMAE via a protease-sensitive linker, Vat-Cit. The drug is mainly suitable for classical Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (sALCL), which was approved by the NMPA in China in 2020 for the treatment of patients with relapsed or refractory sALCL and CD30-positive HL, and is the second ADC approved for marketing in China.
-
European Radiology: The value of radiomics models in predicting temporal lobe radiation damage in nasopharyngeal carcinoma
Time of Update: 2022-11-04
(b) Training cohort and (c) Validation cohort radiology nomogram calibration curves in the cohortIn this study, a machine learning method was developed and validated to predict and evaluate radiation-induced temporal lobe injury (RTLI) in patients with nasopharyngeal carcinoma (NPC) through pre-treatment temporal lobe MRI images.
-
Eur Urol Oncol: In penile cancer, how does mixed tracer-guided sentinel lymph node recognition perform?
Time of Update: 2022-11-04
Oct 2022 Studies have shown that mixed indocyanine green (ICG)-99mTc-nanocolloid tracer improves sentinel lymph node (SN) recognition compared to traditional dynamic sentinel lymph node biopsy (DSNB).
Oct 2022 Studies have shown that mixed indocyanine green (ICG)-99mTc-nanocolloid tracer improves sentinel lymph node (SN) recognition compared to traditional dynamic sentinel lymph node biopsy (DSNB).
-
CD20 CAR-T therapy ORR reaches 100%, and CAR-T at home and abroad may usher in a wave of listing
Time of Update: 2022-11-04
October 31, 2022 /eMedClub News/--Bio, a biopharmaceutical company, recently announced the latest Phase 1/2 clinical trial of its CD20-targeted CAR-T therapy MB-106 for the treatment of multiple hematological tumors, the results of which will be presented at the 11th International Symposium on Waldenstrom Macroglobulinemia 。 MB-106 is a fully human, third-generation, CD20-targeted CAR-T cell therapy containing 4-1BB and CD28 co-stimulatory domains, and its modified IgG1 spacer eliminates FcR binding.
-
【Talking about bowel cancer|】Professor Qiu Meng: Longer survival, more hope, solve the dilemma of the post-line treatment of metastatic colorectal cancer
Time of Update: 2022-11-04
Professor Chen Zhiyu|: Precise diagnosis and treatment, "target" to grasp the future, focus on the exploration of targeted therapy for colorectal cancerThis platform aims to deliver more medical information to healthcare professionals.
-
Cancer Cell: Aerobic exercise can reprogram the immune system and enhance anti-tumor immunity
Time of Update: 2022-11-04
Exercise promotes the survival of IL-15-sensitive CD8 T cells and doubles the number of home-based pancreatic ductal adenocarcinoma (PDAC) tumors in mice, resulting in effector T cells that have been shown by other studies to kill cancer cells.
-
Know Yourself: Regulatory Interpretation and Pre-market Compliance Strategies for Cell Therapy in China and the United States
Time of Update: 2022-11-04
The United States is the world's largest cell therapy research and development country, with 374 gene and cell therapy (CGT) clinical trials registered in the INFORMA drug database, and the United Sta
-
European Radiology: How can imaging be used to assess intratumoral immune status in non-small cell lung cancer?
Time of Update: 2022-11-04
In patients with NSCLC undergoing surgical resection (Resec1; Resec2； The internal cohort Resec3, n=419; the external cohort Resec4, n=96; and the TCIA cohort Resec5, n=55) explored the prognostic value of iEDI.
-
Cell Res: Zhao Yao/Ding Chen/Zhang Qilin of Fudan University on the integrin genomic characterization of major histological types of pituitary neuroendocrine tumors
Time of Update: 2022-11-04
Only three TFs (PIT1, TPIT, and SF1) are currently used to describe the major PitNET cell lineages, although patients exhibit different hormone secretion profiles and different clinical prognosis that these together indicate additional TFs may be involved in tumorigenesis.
-
A weekly inventory of "tailor-made" therapeutic cancer vaccines and early clinical data of multiple cancer therapies is eye-catching
Time of Update: 2022-11-04
Bria-IMT: Published Phase 1 Clinical Trial DataBriaCell Therapeutics has published data from a Phase 1 clinical trial of its cell candidate, Bria-IMT, in combination with Incyte's PD-1 inhibitor, retifanlimab, for the treatment of advanced breast cancer 。 Bria-IMT is a human breast cancer cell line expressing Her2/neu and is designed to produce and secrete breast cancer antigens and granulocyte-macrophage colony-stimulating factor (GM-CSF), which promotes dendritic cell-based antigen presentation and activates the immune system.
-
You Han's team at Xiamen University discovered that acetylation modifications dynamically regulate the nucleoplasmic localization of oncogenigens and the molecular mechanism of tumor invasion and metastasis
Time of Update: 2022-11-04
On October 26, 2022, the team of You Han of Xiamen University published a research paper entitled "METTL3 acetylation impedes cancer metastasis via fine-tuning its nuclear and cytosolic functions" in Nature Communications 。 The study identified an acetylation-dependent regulatory mechanism that determines METTL3 subcellular localization, which may provide mechanistic clues for the development of therapeutic strategies against breast cancer metastasis.
-
European Radiology: Prediction by CT radiomics of recurrence-free survival after gallbladder cancer
Time of Update: 2022-11-04
b Relapse-free survival differs significantly between the three risk subgroupsIn this study, the radiomic features for predicting GBC RFS were developed and extracted according to preoperative contrast-enhanced CT, and a nomogram to optimize the risk stratification and individualized risk prediction of RFS was established by combining it with pathological factors, which could realize the non-invasive early identification of high-risk GBC patients and promote the formulation of personalized treatment plans for GBC patients.
-
【CSCO 2022 Prospect】Current status of diagnosis and treatment of betel nut-related oral cancer
Time of Update: 2022-11-04
com/s/l7ki6OVePnKFPPoZMJNCrA Areca catechu L is a plant in the family Betel nut, widely distributed in Southeast Asia, tropical Asia, East Africa and parts of Europe, and the Pacific Islands, and its fruit can be eaten fresh or processed.
-
Based on the unique design and mechanism, T-DXd opens up a sea of stars for HER2-positive advanced gastric cancer
Time of Update: 2022-11-04
*For medical professionals only to read and refer from structural design, mechanism of action to research progress, revealing the mystery of T-DXd in the treatment of HER2-positive advanced gastric ca
-
ASTRO 2022: Postoperative iSRT plus degarelix improves MFS in prostate cancer with elevated PSA
Time of Update: 2022-11-04
In prostate cancer patients with persistently high prostate-specific antigen (PSA) levels after radical prostatectomy (RP), short-term treatment with androgen deprivation therapy (ADT) with the androgen deprivation therapy (ADT) agent Firmagon improves metastasis-free survival (MFS), the results of this Phase 2 GETUG-AFU 22 trial were presented at the 2022 American Society of Radiation Oncology (ASTRO) Annual Meeting。The GETUG-AFU 22 study is a multicenter, randomized study.
-
Brain MRI to see the "traitor head" sign? Image representation
Time of Update: 2022-11-04
： ， 。 ， ， Recently met 1 patient, the imaging performance is amazing, manifested as a semi-annular FLAIR high-intensity foci around the brainstem, diffusion is limited, not strengthened, the image is called "traitor head sign", further examination for lung cancer meningeal metastasis, Professor Tang Wei of the Department of Neurology, Xinhua Hospital Affiliated to Dalian University led everyone to a detailed analysis.
-
Practical dry goods! Summary of Radiation Therapy for Non-Small Cell Lung Cancer!
Time of Update: 2022-11-04
Para-aortic lymph nodes (ascending aorta or phrenic nerve) Diffusion characteristics Clinical diagnosis, staging Imaging tests Radiation therapy for lung cancer Radiation therapy techniques for lung cancer Comprehensive treatment of lung cancer References:[ 1 ] CHEN Wanqing, SUN Kexin, ZHENG Rongshou.
-
Be careful of the "black rose sign" of the esophagus [YXZX093]
Time of Update: 2022-11-04
One of the manifestations of esophageal cancer under barium meal angiography, showing local irregular narrowing of the esophagus (yellow arrow: dried roses), proximal esophageal dilation (withered ros
-
One-step solution to accurate extraction of patent and literature data! No download required, log in and use!
Time of Update: 2022-11-04
By analyzing and researching the data in patents or documents, and mining the hidden information behind the data, the research time can be greatly shortened and the R&D cost can be saved. However, due
